Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease

Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease

BackgroundCrohn’s disease (CD) is characterized by excessive protease activity and extracellular matrix (ECM) remodeling. To date, 30–50% of patients experience non-response to anti-TNF-α treatment. This study aimed to assess whether serological biomarkers of ECM turnover could monitor or predict re...

Full description

Bibliographic Details
Main Authors: Marta S. Alexdottir, Arno R. Bourgonje, Morten A. Karsdal, Martin Pehrsson, Roberta Loveikyte, Hendrik M. van Dullemen, Marijn C. Visschedijk, Eleonora A. M. Festen, Rinse K. Weersma, Klaas Nico Faber, Gerard Dijkstra, Joachim H. Mortensen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Medicine
Subjects:
Crohn’s disease
infliximab
TNF-α antagonists
biomarkers
collagen
fibrosis
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.933872/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.933872/full

Similar Items